Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPS Capstone Therapeutics	$1.23 -13.4%	$1.50	$0.96 ▼ $16.18	$6.86M	-0.8	1.23 million shs	577,088 shs
PASG Passage Bio	$7.04	$6.89	$5.12 ▼ $26.60	$22.39M	1.81	27,950 shs	8,774 shs
QTTB Q32 Bio	$1.72 -5.5%	$1.90	$1.35 ▼ $53.79	$20.98M	N/A	628,869 shs	105,522 shs
SONN Sonnet BioTherapeutics	$3.55 -1.7%	$3.72	$1.08 ▼ $19.30	$23.96M	1.04	1.60 million shs	266,392 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPS Capstone Therapeutics	-16.96%	+30.28%	-10.97%	-22.83%	+141,999,900.00%
PASG Passage Bio	-5.76%	+1.59%	-5.38%	-2.17%	-57.07%
QTTB Q32 Bio	-7.61%	+0.55%	-17.65%	-0.55%	-95.35%
SONN Sonnet BioTherapeutics	+0.56%	+13.17%	-9.52%	+212.55%	-41.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	3.9918 of 5 stars	3.5	5.0	0.0	0.0	3.8	2.5	1.3
QTTB Q32 Bio	2.8043 of 5 stars	3.1	4.0	0.0	0.0	2.9	1.7	0.6
SONN Sonnet BioTherapeutics	3.2349 of 5 stars	3.5	4.0	0.0	0.0	2.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPS Capstone Therapeutics	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$91.75	1,185.01% Upside
QTTB Q32 Bio	2.25	Hold	$12.17	606.13% Upside
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	461.80% Upside

Current Analyst Ratings Breakdown

Latest CAPS, PASG, SONN, and QTTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PASG Passage Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$260.00 ➝ $67.00
8/13/2025	PASG Passage Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPS Capstone Therapeutics	$44.88M	0.16	N/A	N/A	$4.70 per share	0.27
PASG Passage Bio	N/A	N/A	N/A	N/A	$12.04 per share	N/A
QTTB Q32 Bio	$1.16M	18.12	N/A	N/A	($1.00) per share	-1.72
SONN Sonnet BioTherapeutics	$20K	1,201.50	N/A	N/A	($0.45) per share	-7.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPS Capstone Therapeutics	-$2.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	-$64.77M	-$18.16	N/A	N/A	N/A	N/A	-103.87%	-59.95%	11/12/2025 (Estimated)
QTTB Q32 Bio	-$47.73M	-$4.30	N/A	N/A	N/A	N/A	-2,709.70%	-61.16%	11/6/2025 (Estimated)
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-4,646.10%	-342.21%	N/A

Latest CAPS, PASG, SONN, and QTTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	CAPS Capstone Therapeutics	N/A	-$0.13	N/A	-$0.13	N/A	$12.85 million
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	-$0.95	-$0.46	-$0.95	N/A	N/A
8/12/2025	Q2 2025	PASG Passage Bio	-$4.00	-$2.96	+$1.04	-$2.96	N/A	N/A
8/6/2025	Q2 2025	QTTB Q32 Bio	-$1.14	-$0.78	+$0.36	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPS Capstone Therapeutics	0.22	0.97	0.41
PASG Passage Bio	N/A	3.05	3.05
QTTB Q32 Bio	1.68	5.06	5.06
SONN Sonnet BioTherapeutics	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPS Capstone Therapeutics	2.55%
PASG Passage Bio	53.48%
QTTB Q32 Bio	31.32%
SONN Sonnet BioTherapeutics	9.45%

Insider Ownership

Company	Insider Ownership
CAPS Capstone Therapeutics	42.80%
PASG Passage Bio	4.30%
QTTB Q32 Bio	40.00%
SONN Sonnet BioTherapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPS Capstone Therapeutics	38	5.58 million	3.19 million	N/A
PASG Passage Bio	130	3.18 million	3.04 million	Optionable
QTTB Q32 Bio	39	12.20 million	7.32 million	N/A
SONN Sonnet BioTherapeutics	10	6.75 million	6.62 million	Not Optionable

CAPS, PASG, SONN, and QTTB Headlines

Recent News About These Companies

Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices

August 25 at 3:38 PM | msn.com

Sonnet BioTherapeutics (NASDAQ:SONN) Upgraded at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Sonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting Standards

August 15, 2025 | msn.com

Sonnet Releases Virtual Investor "What This Means" Segment

August 11, 2025 | globenewswire.com

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

August 6, 2025 | msn.com

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

August 4, 2025 | globenewswire.com

Beyond BTC and ETH: The Companies Turning to Alternative Crypto Treasury Assets

August 2, 2025 | msn.com

Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao

August 1, 2025 | tipranks.com

Solana-based treasury model goes global as DeFi Development launches franchise

July 17, 2025 | msn.com

WLFI tokens to become tradable after World Liberty holders’ vote

July 17, 2025 | msn.com

Hyperliquid Strategies Inc. plan for $583M treasury boosts HYPE price

July 16, 2025 | cointelegraph.com

Sonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE Treasury

July 15, 2025 | thecurrencyanalytics.comT

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

July 15, 2025 | msn.com

Public Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New Deal

July 14, 2025 | coinspeaker.com

Sonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.

July 14, 2025 | marketwatch.com

Why did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?

July 14, 2025 | tokenist.comT

Hyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrand

July 14, 2025 | fxstreet.com

HYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid Strategies

July 14, 2025 | msn.com

Massive deal sends biotech stock rallying 367%

July 14, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)

July 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPS, PASG, SONN, and QTTB Company Descriptions

Capstone Therapeutics NASDAQ:CAPS

$1.23 -0.19 (-13.38%)

As of 04:00 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Passage Bio NASDAQ:PASG

$7.04 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.14 +0.10 (+1.42%)

As of 05:18 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Q32 Bio NASDAQ:QTTB

$1.72 -0.10 (-5.49%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 +0.14 (+8.08%)

As of 05:11 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Sonnet BioTherapeutics NASDAQ:SONN

$3.55 -0.06 (-1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$3.66 +0.11 (+3.10%)

As of 05:53 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time